Status:

WITHDRAWN

Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings

Lead Sponsor:

University of Alabama at Birmingham

Collaborating Sponsors:

University of Lagos, Nigeria

Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso

Conditions:

Intrapartum Fetal Distress

Neonatal Asphyxia

Eligibility:

All Genders

Up to 40 years

Phase:

PHASE3

Brief Summary

The goal of this feasibility pilot clinical trial is to determine if sildenafil citrate 50mg orally, up to three times during labor, can: 1) reduce perinatal mortality and/or bag and mask ventilation ...

Detailed Description

Pregnant women with planned vaginal deliveries will be screened for eligibility. After informed consent obtained, subjects will be randomly assigned (using computer generated, stratified randomization...

Eligibility Criteria

Inclusion

  • Pregnant women presenting in early labor with a term pregnancy (≥ 37 weeks to 41wks 6days gestation )
  • Early labor will be defined as cervical dilation less than 7cm
  • Gestational age will be calculated from the most reliable variable using the following hierarchy of reliability: 2) gestational dating ultrasound completed at any time during the pregnancy (with preference to the earliest exam); 2) date of last menstrual period if menses are regular.
  • Planned vaginal delivery and admission to health facility with clear plan for spontaneous or induced vaginal delivery
  • Maternal age ≥ 18yrs

Exclusion

  • Unknown gestational age
  • Non-cephalic fetal presentation
  • Plan for cesarean delivery prior to enrollment
  • Previous uterine scar (cesarean section and/or myomectomy)
  • Advanced stage of labor (7 cm or greater cervical dilation per local standards) and pushing, or too distressed to understand, confirm, or give informed consent regardless of cervical dilation
  • Not capable of giving consent due to other health problems, such as obstetric emergencies (i.e. antepartum hemorrhage) or mental disorder
  • Maternal contraindication to sildenafil therapy, such as hypersensitivity to nitrates or nitrites
  • Recognized major structural fetal anomaly
  • Previous randomization in the trial

Key Trial Info

Start Date :

May 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 30 2026

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT06522854

Start Date

May 1 2025

End Date

November 30 2026

Last Update

September 16 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Lagos Island Maternity Hospital

Lagos, Lagos, Nigeria, 101001

2

University Teaching Hospital, University of Lagos

Lagos, Lagos, Nigeria, 102215

3

Mother and Child Hospital

Surulere, Lagos, Nigeria, 101241

4

Ladoke Akintola University of Technology Teaching Hospital

Ogbomoso, Oyo State, Nigeria, 210271